The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. More Details
Excellent balance sheet and fair value.
Share Price & News
How has United Laboratories International Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3933 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 3933's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 3933 exceeded the Hong Kong Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: 3933 exceeded the Hong Kong Market which returned 11.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is United Laboratories International Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StThe United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?
2 weeks ago | Simply Wall StCan You Imagine How United Laboratories International Holdings' (HKG:3933) Shareholders Feel About The 46% Share Price Increase?
Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3933 (HK$5.95) is trading below our estimate of fair value (HK$28.01)
Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3933 is poor value based on its PE Ratio (15.3x) compared to the HK Pharmaceuticals industry average (10.8x).
PE vs Market: 3933 is poor value based on its PE Ratio (15.3x) compared to the Hong Kong market (11.3x).
Price to Earnings Growth Ratio
PEG Ratio: 3933 is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: 3933 is overvalued based on its PB Ratio (1.2x) compared to the HK Pharmaceuticals industry average (1.1x).
How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3933's forecast earnings growth (15.9% per year) is above the savings rate (1.6%).
Earnings vs Market: 3933's earnings (15.9% per year) are forecast to grow slower than the Hong Kong market (22.1% per year).
High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3933's revenue (7.1% per year) is forecast to grow slower than the Hong Kong market (13.7% per year).
High Growth Revenue: 3933's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (12.7%).
How has United Laboratories International Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3933 has a large one-off gain of CN¥240.2M impacting its June 30 2020 financial results.
Growing Profit Margin: 3933's current net profit margins (6.4%) are lower than last year (11.3%).
Past Earnings Growth Analysis
Earnings Trend: 3933's earnings have grown significantly by 54.2% per year over the past 5 years.
Accelerating Growth: 3933's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3933 had negative earnings growth (-38.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-12.5%).
Return on Equity
High ROE: 3933's Return on Equity (7%) is considered low.
How is United Laboratories International Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 3933's short term assets (CN¥8.2B) exceed its short term liabilities (CN¥4.7B).
Long Term Liabilities: 3933's short term assets (CN¥8.2B) exceed its long term liabilities (CN¥2.6B).
Debt to Equity History and Analysis
Debt Level: 3933's debt to equity ratio (41.6%) is considered high.
Reducing Debt: 3933's debt to equity ratio has reduced from 78.7% to 41.6% over the past 5 years.
Debt Coverage: 3933's debt is well covered by operating cash flow (51.6%).
Interest Coverage: 3933's interest payments on its debt are well covered by EBIT (6.3x coverage).
What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 3933's dividend (1.39%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.21%).
High Dividend: 3933's dividend (1.39%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.57%).
Stability and Growth of Payments
Stable Dividend: 3933's dividend payments have been volatile in the past 10 years.
Growing Dividend: 3933's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21.3%), 3933's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3933's dividends in 3 years are forecast to be thoroughly covered by earnings (14.4% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
United Laboratories International Holdings has no CEO, or we have no data on them.
|Executive Chairman||7.58yrs||CN¥3.27m||0.89% |
|Vice Chairman||7.58yrs||CN¥3.17m||0.0012% |
|VP & Executive Director||10yrs||CN¥2.28m||0.000010% |
|VP & Executive Director||10yrs||CN¥2.28m||0.011% |
|Global Director of Intermediate & Bulk Medicine and Executive Director||7.42yrs||CN¥3.07m||0.0064% |
|VP & Executive Director||10yrs||CN¥2.28m||no data|
|Independent Non-Executive Director||13.5yrs||CN¥204.00k||no data|
|Independent Non-Executive Director||11.67yrs||CN¥204.00k||no data|
|Independent Non-Executive Director||7.92yrs||CN¥204.00k||no data|
Experienced Board: 3933's board of directors are seasoned and experienced ( 10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.
The United Laboratories International Holdings Limited's company bio, employee growth, exchange listings and data sources
- Name: The United Laboratories International Holdings Limited
- Ticker: 3933
- Exchange: SEHK
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$10.950b
- Shares outstanding: 1.84b
- Website: https://www.tul.com.cn
Number of Employees
- The United Laboratories International Holdings Limited
- 6 Fuk Wang Street
- Yuen Long Industrial Estate
- Yuen Long
- New Territories
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|3933||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Jun 2007|
|UNJ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2007|
|ULIH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2007|
|3933||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Jun 2007|
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through three segm...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/28 10:11|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.